Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | THRB | P10828 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | PDE3B | Q13370 | 15/20 | 0.70 |
| ▸ | PDE3A | Q14432 | 15/20 | 0.70 |
| ▸ | SLFN12 | Q8IYM2 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | PDE4A | P27815 | 2/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7275175 | 0.86 | GALR3 (0.76) | GALR3MAPTTHRBALDH1A1GAA | |
| SCHEMBL16156985 | 0.85 | MAPT (1.00) | GALR3MAPTTHRBALDH1A1GAA | |
| SCHEMBL30093776 | 0.85 | MAPT (1.00) | GALR3MAPTTHRBALDH1A1GAA | |
| SCHEMBL5332160 | 0.85 | MAPT (1.00) | GALR3MAPTTHRBALDH1A1GAA | |
| SCHEMBL10333605 | 0.85 | GALR3 (0.74) | GALR3MAPTTHRBALDH1A1GAA | |
| SCHEMBL10333516 | 0.85 | GALR3 (0.74) | GALR3MAPTTHRBALDH1A1GAA | |
| SCHEMBL10333497 | 0.85 | PDE3B (0.55) | GALR3MAPTTHRBALDH1A1GAA | |
| SCHEMBL31397911 | 0.83 | PDE3B (0.72) | GALR3MAPTTHRBALDH1A1GAA | |
| SCHEMBL10332954 | 0.83 | GALR3 (0.74) | GALR3MAPTTHRBALDH1A1GAA | |
| SCHEMBL10333665 | 0.83 | GALR3 (1.00) | GALR3MAPTTHRBALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4954499-A | Pyridazinone derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1990-09-04 | — | — | US | claimed |
| EP-0279283-A2 | Pyridazinone derivatives | MERCK PATENT GmbH (DE) | 1988-08-24 | — | — | EP | claimed |
| CN-119431326-A | Pimobendan Synthesis method of pill | 辽宁孚音生物科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119431250-A | Pimo-benzol pill intermediate and synthesis method thereof | 辽宁孚音生物科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-8680101-B2 | Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use | EUROVET ANIMAL HEALTH B.V. (NL) | 2014-03-25 | — | — | US | disclosed |
| EP-2338493-A1 | Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use | Eurovet Animal Health B.V. (NL) | 2011-06-29 | — | — | EP | disclosed |
| US-20110152283-A1 | CRYSTALLINE PIMOBENDAN, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION AND USE | EUROVET ANIMAL HEALTH B.V. (NL) | 2011-06-23 | — | — | US | disclosed |
| EP-0327800-B1 | 6-PHENYLDIHYDRO-3(2H)-PYRIDAZINONES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS | HEUMANN PHARMA GMBH & CO (DE) | 1992-05-27 | — | — | EP | disclosed |
| US-5026705-A | Benzimidazolylpyridazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1991-06-25 | — | — | US | disclosed |
| US-4954499-A | Pyridazinone derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1990-09-04 | — | — | US | disclosed |
| US-4954501-A | INOTROPIC AGENTS | HEUMANN PHARMA GMBH & CO. (DE) | 1990-09-04 | — | — | US | disclosed |
| US-4923869-A | INOTROPIC, VASODILATING, AND ANTITHROMBOTIC AGENTS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1990-05-08 | — | — | US | disclosed |
| EP-0327800-A2 | 6-Phenyldihydro-3(2H)-pyridazinones, process for their preparation and medicines containing these compounds | HEUMANN PHARMA GMBH & CO (DE) | 1989-08-16 | — | — | EP | disclosed |
| EP-0193013-B1 | BENZIMIDAZOLYL-PYRIDAZINONES | MERCK PATENT GmbH (DE) | 1989-04-19 | — | — | EP | disclosed |
| EP-0279283-A2 | Pyridazinone derivatives | MERCK PATENT GmbH (DE) | 1988-08-24 | — | — | EP | disclosed |
| EP-0193013-A2 | Benzimidazolyl-pyridazinones | MERCK PATENT GmbH (DE) | 1986-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152283-A1 | CRYSTALLINE PIMOBENDAN, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION AND USE | PIM1, PIM3, PIM2 | GALR3 3730/4885MAPT 669/4885THRB 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.